Welcome
Support Centre
13 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
An International Collaborative Trial for Relapsed and Refractory Acute Lymphobalstic Leukaemia
ISRCTN ISRCTN45724312
ClinicalTrials.gov identifier
Public title An International Collaborative Trial for Relapsed and Refractory Acute Lymphobalstic Leukaemia
Scientific title
Acronym UKALLR3
Serial number at source N/A
Study hypothesis To examine the biology of relapsed Acute Lymphoblastic Leukaemia (ALL) and improve its outcome using a combination of chemotherapy and nationally standardised approach to Haematopoietic Stem Cell Transplantation (HSCT).
Ethics approval Ethics approval received from the Multicentre Research Ethics Commitee (ref: 02/9/21)
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL)
Participants - inclusion criteria 1. All children aged 1 - 18 years who have been previously diagnosed to have acute lymphoblastic leukaemia and have either relapsed after treatment or have primary refractory disease
2. For children who have relapsed, only those in whom this is the first relapse are eligible
3. Provide signed, written informed consent from parent and/or guardian
4. Protocol to have received national local ethical committee approval
Participants - exclusion criteria 1. Children less than 1 year old and young adults of 18 years of age and older
2. Children in whom this is not the first relapse of their disease
3. Children with first relapse who have already received chemotherapy or radiotherapy prior to starting R3
4. Children with mature B cell ALL
Anticipated start date 06/01/2003
Anticipated end date 01/01/2010
Status of trial Completed
Patient information material
Target number of participants 480
Interventions No additional procedures are required in the trial. The trial drugs have already been used in previous paediatric oncology trials for many years.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK (UK) (ref: ONPG1A1R) - Funding for trial manager
Trial website
Publications
Contact name Prof  Vaskar  Saha
  Address Dept of Paediatric Oncology and Haematology
1st Floor Eva Luckes House
Royal London Hospital
  City/town London
  Zip/Postcode E1 1BB
  Country United Kingdom
  Tel +44 (0)20 7377 7758
  Fax +44 (0)20 7377 7796
  Email vaskar.saha@cancer.org.uk
Sponsor Barts and the London NHS Trust (UK)
  Address Research and Development Department
3rd Floor Rutland House
42-46 New Road
Whitechapel
  City/town London
  Zip/Postcode E1 2AX
  Country United Kingdom
  Sponsor website: http://www.bartsandthelondon.org.uk/
Date applied 01/10/2003
Last edited 14/11/2007
Date ISRCTN assigned 01/10/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central